StockNews.AI
BMY
StockNews.AI
29 days

Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

1. BMS's application for Sotyktu to treat psoriatic arthritis has been accepted. 2. FDA's review could influence BMY's growth prospects positively.

2m saved
Insight
Article

FAQ

Why Bullish?

FDA acceptance indicates potential for new revenue streams similar to historical approvals that boosted other biotech stocks.

How important is it?

New drug approvals can significantly impact stock valuation; prior examples include successful launches by competitors.

Why Long Term?

If approved, Sotyktu could establish BMY in the psoriatic arthritis market, leading to sustained revenue growth.

Related Companies

ABBVAMGNVRTX
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--BMS's Supplemental New Drug Application for Sotyktu for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review.

Related News